China NMPA Drug Inspection - Guangdong Hongying Technology Co., Ltd. - Chloramphenicol eye drops

The Guangxi Zhuang Autonomous Region Food and Drug Administration (GXFDA) issued its 10th Drug Quality Announcement on November 30, 2017, following a comprehensive drug sampling plan. The initiative focused on strengthening drug quality supervision to safeguard public health. The announcement reported that five batches of drug preparations failed to meet quality standards during inspections.

Specifically, Guangxi Hongying Technology Co., Ltd. was identified for four batches of Chloramphenicol Drops (batches 16102301, 16113001, 16101101, 17010501), which were found to have non-compliant related substances, indicating impurity issues. Additionally, the Liuzhou Traditional Chinese Medicine Hospital Preparation Room's Nanxilin solution (batch 20170313) failed to meet content volume specifications, suggesting an inaccurate active ingredient dosage.

These inspections were conducted based on the Guangxi Drug Sampling Plan and in accordance with the Chinese Pharmacopoeia (2015 edition). In response to these findings, the GXFDA has mandated immediate control measures, including sealing, seizing, and suspending the sale of the substandard drugs. The agency is also pursuing investigations and legal actions against the responsible entities to address these quality violations.